Overview
Lobbying Costs
75,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Baxter Healthcare SA (Baxter)
EU Transparency Register
84050217165-45 First registered on 16 Nov 2011
Goals / Remit
Description:
Baxter’s mission to save and sustain lives inspires our work and our commitment to deliver products and services that are essential building blocks of healthcare.
Baxter touches millions of lives every day. Our products and services are essential building blocks of healthcare.
Baxter’s products and therapies can be found on nearly every floor, in every department, in almost every hospital worldwide, in clinics and in the home. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.
Our mission to save and sustain lives inspires our work and our commitment to expanding access to care, providing cost-effective healthcare solutions, delivering quality products and advancing innovations for the world.
devices and pharmaceuticals to create products that advance patient care worldwide.
Goals:
• Baxter interacts with the EU Institutions on the legislation which has an impact on the healthcare industry through its participation in debates and public consultations
• Ensure equal access to treatment and technologies to patients
• Apply innovative science to develop specialty therapeutics and medical products that save and sustain patients’ lives
• Improve conditions for prevention, treatment and care to address unmet needs
• Raise awareness and support the voice of patients suffering from chronic and life threatening diseases
• Support policy development aiming at improving regulatory processes for the healthcare sector and the competitiveness of research and industryMain EU files targeted
EU initiatives, policies and legislative files related to the field of healthcare policy and patient access
Address
Head Office
Thurgauerstrasse, 130
Glattpark
Zurich 8152
SWITZERLANDEU Office
boulevard d'Angleterre 2-4
Braine l'Alleud 1420
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 22 Jan 2020
Name Start date End Date Ms Ioana Enache 29 Jan 2020 29 Jan 2021 Mr Frederik ULRICHS 31 Aug 2017 20 Apr 2018 Mr Frederik ULRICHS 15 Mar 2016 12 Mar 2017 Ms Maria RODRIGUEZ SANCHEZ 12 Mar 2015 20 Oct 2015 Mr Toon DIGNEFFE 06 Mar 2015 22 Oct 2015 Mr Frederik ULRICHS 05 Mar 2015 03 Mar 2016 Ms Maria RODRIGUEZ SANCHEZ 11 Feb 2014 11 Feb 2015 Ms Astrid Jankowitsch 29 Nov 2014 22 Oct 2015 Mr Frederik ULRICHS 25 Feb 2014 03 Mar 2015 Mr Toon DIGNEFFE 11 Feb 2014 11 Feb 2015 Mrs Maria RODRIGUEZ SANCHEZ 11 Feb 2014 27 Jan 2015 Mr Frederik ULRICHS 19 Mar 2013 25 Feb 2014 Mr Toon DIGNEFFE 12 Mar 2013 12 Feb 2014 Mrs Maria RODRIGUEZ SANCHEZ 12 Mar 2013 12 Feb 2014 Toon DIGNEFFE 29 Feb 2012 08 Feb 2013 Frederik ULRICHS 27 Feb 2012 08 Feb 2013 Mrs Maria RODRIGUEZ SANCHEZ 08 Feb 2012 08 Feb 2013 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
MedTech Europe, Amcham EU, MNI (Medical Nutrition Industry), Friends of Europe
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
75,000€
EU grant income for closed financial year
173,855 € (Source: Horizon 2020 IMPROVE PD)
Other financial info
IMPROVE-PD is a project funded by the Horizon 2020 Framework
Programme under the initiative Marie Sklodowska-Curie Innovative
Training Networks.
IMPROVE-PD's main aim is to connect leading academic and
industrial researchers who will collaborate in the shared goal of
understanding the mechanisms of inflammation-driven
cardiovascular disease in Peritoneal Dialysis (PD) patients,
developing individualized approaches to identify those at risk, and
testing new therapies in them.
PROJECT DESCRIPTION ESR1
The primary target of WP1 is to define the baseline and longitudinal CV risk profile of PD patients, with focus on patients at the extremes (low and high) CV risk (such as the "inflamed patient", personalized prognostic modelling).
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Legislative initiatives and policy issues in the field of healthcare policy and patient access
Other activities
Legislative initiatives and policy issues in the field of healthcare policy and patient access.
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 26 Feb 2015 Location Brussels Subject Blood directive Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)